Liisa Bayko
Stock Analyst at Evercore ISI Group
(4.55)
# 279
Out of 4,761 analysts
83
Total ratings
55.88%
Success rate
24.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $47.91 | +106.64% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $21.98 | +104.73% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $9.21 | +30.29% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $1.92 | +160.42% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.45 | +55.49% | 2 | Dec 11, 2024 | |
| SVRA Savara | Downgrades: In-Line | $7 → $5 | $2.69 | +85.87% | 3 | Nov 13, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $20.02 | +74.83% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $336.23 | +7.07% | 9 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $250.59 | +3.76% | 1 | Jun 25, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: In-Line | $27 → $2 | $2.37 | -15.61% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.13 | +76.99% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $11.06 | +198.37% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $51.84 | -26.70% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $438 | $484.24 | -9.55% | 17 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $42.59 | +87.84% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $6.81 | +164.32% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $6.43 | +288.80% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $8.03 | +672.10% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $7.51 | +366.05% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $28.58 | -16.03% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $9.32 | +222.06% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.42 | +192.40% | 1 | Feb 5, 2020 |
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $47.91
Upside: +106.64%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $21.98
Upside: +104.73%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $9.21
Upside: +30.29%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $1.92
Upside: +160.42%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.45
Upside: +55.49%
Savara
Nov 13, 2024
Downgrades: In-Line
Price Target: $7 → $5
Current: $2.69
Upside: +85.87%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $20.02
Upside: +74.83%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $336.23
Upside: +7.07%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $250.59
Upside: +3.76%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: In-Line
Price Target: $27 → $2
Current: $2.37
Upside: -15.61%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.13
Upside: +76.99%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $11.06
Upside: +198.37%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $51.84
Upside: -26.70%
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $484.24
Upside: -9.55%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $42.59
Upside: +87.84%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $6.81
Upside: +164.32%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $6.43
Upside: +288.80%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $8.03
Upside: +672.10%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $7.51
Upside: +366.05%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $28.58
Upside: -16.03%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $9.32
Upside: +222.06%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.42
Upside: +192.40%